Breast cancer treatment has entered the translational era with the increasing emergence of rationally designed molecular therapeutics, particularly those 
EGFR and HER-2 in Breast Cancer
The EGFR/HER family of tyrosine kinases plays an important role in the development and progression of breast cancer. 1 It includes four known members: EGFR (HER-1 or erbB1), HER-2 (neu or erbB2), and HER-4 (erbB4). Signalling from these receptor tyrosine kinases is triggered by binding of specific ligands, including EGF, transforming growth factor-α (TGF-α), amphiregulin, epiregulin, betacellulin, heparin-binding EGF-like growth factor (HB-EGF) and neuregulins 1-4. 2 Ligands for EGFR, HER-3 and HER-4 are frequently expressed in breast cancer. 3, 4 No ligands for HER-2 have been identified, and analysis of the crystal structure of HER-2 suggests that the receptor is constitutively poised in an active conformation and is capable of forming heterodimers with other ligand-activated HER receptors. 5 The overexpression of both EGFR and HER-2 has been associated with poor prognosis in breast cancer. [6] [7] [8] [9] [10] The HER-2 gene is amplified in approximately 20-25% of breast cancers, and these HER-2-positive tumours constitute a distinct subtype of breast cancer, as demonstrated by recent microarray-based classification of the disease. 11 Although the EGFR protein is frequently overexpressed in breast cancer, EGFR gene amplification is reported in fewer than 10% of breast tumours. 12, 13 EGFR is frequently expressed with HER-2 in breast cancer and co-overexpression of both receptors is associated with worse outcome. 14 EGFR is also frequently overexpressed in basal-like breast cancers, which lack the expression of oestrogen receptor (ER), progesterone receptor (PR) and HER-2 ('triplenegative'). In ER-positive breast tumours, increased expression of EGFR is associated with resistance to endocrine therapy. 15, 16 
HER-2 Inhibitors
Trastuzumab (Herceptin, Genentech), a recombinant humanised monoclonal antibody against HER-2, binds to the extracellular domain of HER-2 and inhibits tumour cell proliferation, enhances response to chemotherapy and induces antibody-dependent cellular cytotoxicity. 17 It is approved for the treatment of both metastatic and early-stage HER-2-positive breast cancer. 18 The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) recently issued guidelines to improve the accuracy of HER-2 testing in breast cancer. 19 The guidelines define HER-2 positivity as an immunohistochemical staining (IHC) score above three, more than six copies of the HER-2 gene by Table 1 ). 23 Combinations of trastuzumab with taxanes, platinum compounds or vinorelbine are safe and show favourable efficacy. 24 The only significant toxicity associated with trastuzumab is cardiac toxicity, and this is particularly problematic when trastuzumab is administered with or following 
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anthracyclines, which also cause cardiotoxicity. Therefore, the concurrent administration of trastuzumab and anthracyclines is not recommended.
Pegylated liposomal doxorubicin (PLD) shows similar activity to conventional doxorubicin, but is associated with a significantly lower risk of cardiotoxicity. 25 Two phase II studies have examined the concurrent administration of PLD and trastuzumab in HER-2-positive metastatic breast cancer and showed that while some patients experienced a reduction in left ventricular ejection fraction (LVEF), none of the patients developed congestive heart failure. 26, 27 A number of ongoing randomised trials are evaluating the combination of PLD and trastuzumab in HER-2-positive breast cancer. 28 The greatest clinical impact of trastuzumab is in the treatment of HER-2-positive early-stage breast cancer, where data from five randomised trials demonstrated a benefit of trastuzumab. The addition of trastuzumab to adjuvant therapy resulted in a 39-52% reduction in disease recurrence (see Table 2 ). [29] [30] [31] [32] A recent meta-analysis of the five adjuvant trials comparing adjuvant trastuzumab plus chemotherapy versus chemotherapy alone showed a significant reduction in mortality (p<0.00001), recurrence (p<0.00001) and rates of metastasis (p<0.00001) for the trastuzumab-containing regimens. 33 The first negative trial of Concurrent administration of trastuzumab with chemotherapy may be more beneficial in adjuvant therapy than sequential treatment. 35 The unplanned interim analysis of the N9831 adjuvant trial, which randomised patients to no trastuzumab, concurrent trastuzumab or sequential trastuzumab with chemotherapy, also suggested a greater benefit for concurrent trastuzumab; the results of this trial may provide an answer to the sequential versus concurrent question.
In the BCIRG006 adjuvant study, trastuzumab, docetaxel and carboplatin (TCH) was compared with doxorubicin/cyclophoshophamide followed by docetaxel alone (AC-T) or in combination with trastuzumab (AC-TH). The TCH combination was derived from laboratory observations of synergy, 36 and at the second interim analysis it showed similar efficacy to the AC-TH arm. 31 Topoisomerase II alpha (TOP2A) co-amplification was detected in one-third of the HER-2-amplified tumours in the BCIRG006 study. 37 The fact that there was no difference in disease-free progression between the anthracycline and non-anthracycline-containing arms of the study 31 suggests that in tumours with co-amplification of both genes, targeting HER-2 with trastuzumab or TOP2A with anthracyclines achieves similar efficacy. 38 Combinations of trastuzumab with hormonal therapies such as tamoxifen and aromatase inhibitors are also currently under investigation. 39 response and time to progression in the trastuzumab plus anastrozole arm. 40 However, the overall response rates were significantly lower than those observed for combinations of trastuzumab with chemotherapy. 41 Induction of antibody-dependent cellular cytotoxicity (ADCC) may be an important mechanism of action for trastuzumab, and several studies are examining whether increasing natural killer cell numbers and activity using interleukin-2 or interleukin-12 could increase efficacy by enhancing the trastuzumab-induced ADCC. 42, 43 Other issues to be resolved regarding the use of trastuzumab in HER-2-positive breast cancer include scheduling Breast Cancer (weekly versus every three weeks), the optimum duration of treatment and whether to continue trastuzumab treatment beyond disease progression. 41 Pertuzumab (Omnitarg™, Genentech) is also a humanised monoclonal antibody against HER-2, but it differs from trastuzumab in its mechanism of action. Pertuzumab binds to domain two of HER-2, sterically blocking a binding pocket necessary for receptor dimerisation and signalling. 44 In vitro studies have shown that pertuzumab combined with trastuzumab is synergistic in HER-2-overexpressing cell lines. 45 A phase II study in patients with metastatic breast cancer with low expression of HER-2 reported that pertuzumab was safe but showed limited activity as a single agent in this population. 46 The overall response rates for these two studies were 22 and 14%, respectively. 50 Combined biomarker analysis for the two studies suggested that metastatic breast cancer patients were more likely to respond if their tumours were ER-and PR-negative or HER-2-overexpressing. 51 A phase III trial of lapatinib plus capecitabine versus capecitabine alone was conducted in patients with HER-2-positive refractory advanced or metastatic breast cancer who were previously treated with anthracycline, taxane and trastuzumab (see Table 1 ). 52 The study demonstrated a significant improvement in median time to progression for lapatinib and capecitabine versus capecitabine alone (6.2 versus 4.3 months; p=0.00013). 53 Importantly, brain metastases were detected less frequently in patients in the combination arm than in the capecitabine-alone group (four versus 13 cases with central nervous system [CNS] involvement at first progression; p=0.045). This may be due to lapatinib's ability to cross the blood-brain barrier. Trastuzumab cannot cross the blood-brain barrier, so is not effective for the treatment of brain metastasis. 54 Cardiotoxicity was reported in only four of 160 patients receiving lapatinib and capecitabine. Thus, cardiotoxicity does not appear to be a significant problem with lapatinib treatment. 52 In fact, a recent study has shown that lapatinib stimulated a metabolic stress response in human cardiac cells, which appears to offer protection against TNF-α-induced cell death. 55 Diarrhoea is the most frequently reported adverse event in lapatinib clinical trials, and this may be due to gastrointestinal toxicity caused by EGFR inhibition. A recent analysis of 2,201 patients demonstrated that lapatinib-induced diarrhoea is usually low-grade, with grade 3 diarrhoea occurring in <10% of patients. 56 Single-agent lapatinib has also been evaluated in a phase II study in patients with relapsed or refractory inflammatory breast cancer. 
EGFR Inhibitors
Gefitinib (Iressa™, AstraZeneca) is a small-molecule tyrosine kinase inhibitor of EGFR that binds reversibly to the ATP-binding site of EGFR. Phase II trials of gefitinib in refractory metastatic breast cancer yielded disappointing response rates of 2-13%. 58 An examination of biological profiles in the tumour tissues from a phase II study of gefitinib in advanced breast cancer suggested that the lack of activity was due to a lack of EGFR dependence in the tested population. 59 A phase II study of gefitinib in combination with paclitaxel and carboplatin as first-line therapy for advanced breast cancer showed no benefit of addition of gefitinib based on previously reported response for the combination of paclitaxel and carboplatin alone. 60 A phase II trial of docetaxel in combination with gefitinib as first-line treatment was conducted in patients with metastatic breast cancer 61 and produced an overall response rate of 54% (22 of 
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Dual Targeting of EGFR and HER-2 in Breast Cancer
Evidence from cell line models and patient samples suggests that dual Table 3 ).
Novel EGFR and HER-2 Inhibitors
Several novel EGFR and HER-2 inhibitors are currently in pre-clinical and clinical development. The inhibitors include monoclonal antibodies and both reversible and irreversible small-molecule tyrosine kinase inhibitors of HER-2, dual inhibitors of EGFR and HER-2 and pan-HER inhibitors (see Table 4 ). 
Hsp90 Inhibition
Hsp90 is a molecular chaperone that regulates the stability and maturation of HER-2 82 and is expressed at higher levels in breast tumours than non-cancerous breast tissue. 83 The inhibition of Hsp90 has been shown to downregulate HER-2 and improve responses to trastuzumab in vitro. 84 A phase I study of tanespimycin (17-AAG) plus trastuzumab has been completed. 85 The combination was well tolerated and showed antitumour activity in patients with trastuzumab-refractory HER-2-positive breast cancers. Hsp90 inhibitors may also have therapeutic benefits in HER-2-negative breast cancers, as Hsp90 inhibition targets a number of key signalling pathways including Akt.
Targeting Downstream Signalling Pathways
The PI3 kinase/Akt pathway is activated by EGFR and HER-2 signalling, and is a key survival and antiapoptotic signal transduction pathway. 
